The specific mechanism of pulmonary arterial hypertension (PAH) remains elusive.
| INTRODUC TI ON
Pulmonary arterial hypertension (PAH) is a chronic disease condition involving in vascular remodelling disease of the lungs, which causes an increase in the pulmonary artery pressure and eventually leading to right heart failure and death. Despite the progress in knowledge has been obtained about potential therapeutic targets and introduction of newer drugs, the 5-year survival rate still remains low. 1 This can be attributed to the ill-understood pathophysiology of PAH, necessitating further exploration of the mechanism of disease development for the development of novel therapeutic strategies.
In recent years, the major efforts have been focused on the differential regulation in the metabolic pathways which may be contributory to PAH pathogenesis. Emerging evidence points towards a metabolic theory of PAH, suggesting that PAH results from the suppression of the mitochondria-based respiration and glucose oxidation (named Warburg effect in cancer metabolism). 2, 3 It causes cells to rapidly proliferate without undergoing apoptosis of cells and accelerates the vascular remodelling in PAH. It is widely regarded that various metabolic changes during the Warburg effect are also essential for the occurrence and maintenance of PAH. 3, 4 In addition, metabolic changes involving fatty acid oxidation and amino acid breakdown are also thought to be involved in the formation of PAH. 5 A deeper understanding of these pathways holds the potential to provide targets for the diagnosis and treatment of PAH. However, due to the complex nature of these metabolic pathways in PAH, a single metabolic pathway affecting the disease pathogenesis and progression is difficult to illustrate. However, large scale metabolomics provides a lucrative alternative to understand the differential regulation of these metabolic pathways involved in PAH. In a seminal study by Zhao et al, 6 the metabolomic heterogeneity of PAH patients was demonstrated in a discovery cohort of a small group of patients (n = 8). Unbiased metabolomic profiles hinted towards possible disruption of the glycolytic pathway with concurrent increase in TCA cycle substrates and metabolites. Using a combination of high-throughput liquid-and-gas-chromatography-based mass spectrometry, the changes in fatty acid oxidation were shown from the resultant metabolites and subsequent changes in arginine pathways were also demonstrated with increase in nitric oxide (NO) production and decreased arginine levels in the lung. Further validation of predicted targets using a panel of 105 circulating plasma metabolites in PAH patients confirmed the association of right ventricular-pulmonary vascular dysfunction with circulating indoleamine 2,3-dioxygenase (IDO)-dependent tryptophan metabolites (TMs), tricarboxylic acid intermediates and purine metabolites. 7 Reports from recent study are also congruent with these findings where they demonstrate a strong strength of association between patient survival and metabolic profiles in PAH. 8 However, the metabolic profile of individuals is dependent on race, sex and dietary habits. Till now, no studies focusing on the metabolomic changes in a primarily Chinese PAH patient cohort have been documented. The current study aimed to fill this gap in knowledge in our study. Employing ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry (UPLC-HRMS) in a non-targeted metabolomics analysis, we aim to explore the metabolic profiles in plasma from PAH patients (idiopathic or congenital heart disease (CHD) associated PAH) and their healthy counterparts. We also investigated the differentially expressed targets in PAH rat model to delineate the changes in the key enzymes involved in glucose and lipid metabolism. This is intended to identify the signature of metabolites for PAH, which can be used for biomarker discovery and potential therapeutic targets for the disease germane. After fasting for 8 hours before right-side heart catheterization, venous blood samples were drawn from the femoral venous and collected in EDTA anticoagulant tubes, centrifuged (1000 g, 10 minutes) and stored at −80°C until required.
| MATERIAL S AND ME THODS

| Sample collection
| Right-side heart catheterization
Right-side heart catheterization was performed by internal jugular vein. Haemodynamic measurements were investigated by a catheter as described previously. 10 Ventricular systolic pressure (RVSP), right ventricular diastolic pressure (RVDP), right atrial pressure (RAP), mean pulmonary vein pressure (mPVP) and pulmonary capillary wedge pressure (PCWP) were documented. Pulmonary vessel resistance (PVR) = mPVP/pulmonary flow (L/min) was calculated.
| Sample preparation and UPLC-HRMS
The method of sample preparation for the metabolomic analysis was in accordance with the sample preparation method by UPLC-HRMS. 11 Briefly, serum samples were prepared by 10 µL serum 
| Data preprocessing and multivariate statistical analysis
Firstly, Profnder and Mass Profler Professional software were used to extract and analyse the original data. Then, the analysed data were imputed to SIMCA-P+(13.0) software for multivariate pattern recognition analysis. We used a principal component analysis (PCA) to highlight potential outliers. Meanwhile, the quality control (QC) samples were analysed by PCA to detect the polymerization and the stability of the method. Orthogonal partial least square-discriminate analysis (OPLS-DA) was applied to the same data sheet to figure out the differences in metabolite in the groups. OPLS-DA was also applied to figure out values of variable importance in projection (VIP) of each metabolite.
Benjamini-Hochberg false discovery rate (FDR) is calculated based on the "BH" method. 13 Student's t test used to compare the levels of metabolite in two independent group, where P values of <.05, VIP > 1.0 and FDR < 0.1 were considered to be significantly altered.
After preliminary screening of different molecules, the metabolites were identified by the following methods: (a) determine Male SD rats (180 g) were obtained from the Hunan SJA Laboratory Animal Co. Rats randomly received an intraperitoneal injection of normal saline (control, n = 12) or monocrotaline (MCT) (Sigma, 60 mg kg −1 ·rat, n = 24) to induce PAH. The rats in control group were examined at the third week (day 21), and rats in MCT group were randomly examined at the second (day 14, n = 12) and third week (day 21, n = 12).
| PAH animal models
| Measurement of RVSP and RVH
Haemodynamic measurement was performed as previously described. 14 
| Total RNA preparation and real-time quantitative PCR analysis
Quantitative real-time PCR was performed as previously described. 15 Total RNA was extracted from lungs or heart tissue using TRIzol (Invitrogen) according to the manufacturer's instructions.
The RNA was reverse-transcribed to cDNA using a RevertAid First 
| Western blotting analysis
Western blotting analysis was performed as previously described. 16 Briefly, the proteins from harvested lung were extracted with RIPA lysis buffer (Beyotime) and separated on sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE) before transferring onto polyvinylidene difluoride (PVDF) membranes. Subsequently, the membranes were blocked with 5% milk PBST solution and then incubated with the following respective antibodies: rabbit monoclonal anti-CD36, rabbit monoclonal anti-GLUT1, rabbit mono- 
| Statistical analysis
Comparisons between multiple groups were conducted using oneway analysis of variance (ANOVA) followed by least significant difference post hoc tests. Comparisons between two groups were 
| RE SULTS
| Basic information of participants
The average age of IPAH patients and CHD-PAH patients was 37.72 ± 10.50 and 31.65 ± 8.29 years with a female predominance ( Table 1 ). The CHD-PAH patients were consisted of ventricular septal defect (55%), atrial septal defect (25%) and patent ductus arteriosus (20%).
| Clinical characteristics
The levels of NT-proBNP, uric acid and total bilirubin in IPAH patients were significantly higher than normal and only the levels of total bilirubin in CHD-PAH patients were significantly higher than normal value ( Table 2 ). The results of cardiac colour ultrasound showed the diameter of right ventricle (RV) and right atrium in IPAH patients was larger than normal value. The diameter of RV in CHD-PAH patients was larger than normal value ( Table 2 ). The results of right-side heart catheterization showed RVSP, RVDP, mPVP and pulmonary vessel resistance were significantly higher than normal value both in IPAH and CHD-PAH patients ( Table 2 ).
| Metabolomic profiles
The results of PCA showed there were no remarkable outliers, and the stability of the method was high (data not shown). Mass Profnder and Mass Profler Professional software were used to extract the raw data and conducted peak extraction, the peak cluster as well as retention time correction. Ultimately, we got the data about massto-charge ratio (m/z), the retention time (RT) and the data matrix of peak area. In positive and negative ion mode, 1175 and 907 variables were obtained, respectively.
OPLS-DA was used to analyse the different metabolites in positive and negative ion mode. The results showed a clear separation in model 1 (IPAH vs Control) ( Figure 1A ,B), model 2 (CHD-PAH vs Control) ( Figure 1C ,D) and model 3 (IPAH vs CHD-PAH) ( Figure 1E ,F). The evaluation parameters of these models were obtained by cross validation of the OPLS-DA model ten times, confirming the model's robust risk-prediction ability (Table S1 ).
And S-plot model was applied to figure out the differential variable. When VIP value of the metabolite was greater than 1.0, it is considered as a significant contribution to the model. Student's t test was used to analyse the difference between two groups. (Table S2) . Among these metabolites, 31 metabolites from PAH patients were significantly up-regulated (n = 22) or down-regulated (n = 9) compared with respective metabolites from healthy controls (Table S2 , Figure 2A,B ).
| Enrichment and clustering of metabolites of interest
The metabolic pathway enrichment and clustering analysis showed 20 pathways were enriched with metabolites of interest which distinguished the IPAH and healthy controls ( Figure 3A ). Among these pathways, beta-oxidation of very long-chain fatty acids, fatty acid metabolism, transfer of acetyl groups into mitochondria, oxidation of branched-chain fatty acids, citric acid cycle, pyruvaldehyde degradation and pyruvate metabolism showed the highest enrichment level ( Figure 3A) .
Seventeen pathways were enriched with metabolites of interest which distinguished the CHD-PAH and healthy controls ( Figure 3B ). Among these pathways, alpha-linolenic acid and linoleic acid metabolism, mitochondrial beta-oxidation of long-chain fatty acids, pyruvate decomposition, oxidation of branched-chain fatty acids, and carnitine synthesis showed the highest enrichment level ( Figure 3B ).
Functional analysis of metabolic pathway showed citric acid cycle (impact 0.125) and phenylalanine metabolic pathway (impact 0.127) were remarkable disturbed in IPAH patients ( Figure 3C ). Malic acid and citric acid in citric acid cycle are significantly regulated in IPAH patients ( Figure 3D ). Alpha-linolenic acid metabolism (impact 0.203) and arachidonic acid metabolism (impact 0.203) were remarkable disturbed in CHD-PAH patients (Data not shown).
| ROC curve analysis of metabolites
In order to assess the diagnostic capacity of the metabolites, the receiver operating characteristic (ROC) curve analysis was applied to the data sheet. The area under the ROC curve for LysoPC, PC, decanoylcarnitine and l-carnitine was 97%, 83%, 79% and 74.4% in IPAH (n = 40)
CHD-PAH (n = 20)
Healthy control (n = 20) IPAH patients, respectively, which indicated LysoPC (18:2(9Z,12Z)) had a good diagnostic ability ( Figure 4A ). The area under the ROC curve for perillic acid, palmitoleic acid, N-Acetyl-d-sphingosine, oleic acid, palmitic acid, 2-Octenoylcarnitine, alpha-linolenic acid, arachidonic acid, docosahexaenoic acid and octadecanoic acid was 96%, 89%, 84.5%, 82.8%, 82%, 79.5%, 79.5%, 76% and 75% in CHD-PAH patients, respectively, which indicated perillic acid had a good diagnostic ability ( Figure 4B ). The joint diagnostic efficacy of selected metabolites above was analysed by random forest method, and the AUC for IPAH or CHD-PAH were 97.7%-98.8% and 95.4%-96.2%, respectively ( Figure 4C,D) .
| Haemodynamic index of MCT-induced PAH rats
In the second week (day 14) and the third week (day 21), mean pulmonary arterial pressure (mPAP) ( Figure S1A ), RVSP ( Figure   S1B ), right ventricular hypertrophy index (RVHI) ( Figure S1C ) and MT% (external diameter/external diameter) ( Figure S1E ) of rats in MCT group were significantly higher than that in control group Figure S1D ).
| Changes of genes and proteins involved in glucose and fatty acid metabolism in lungs of MCTinduced PAH rat model
We investigated the mRNA and protein expression levels of key enzymes in glucose and fatty acid metabolism in lungs. The results showed the mRNA expression levels of PDK1, GLUT1, PKM2, CD36 and FASN were significantly increased in lungs when rats were treated with MCT for 2 or 3 weeks, and mRNA expression of LDHA was significantly increased only in the third week of MCT treatment, compared with the control group (all P < .05) ( Figure 5A ). There was no significant change in mRNA expression levels of GLUT4, PDK4, LDH2, CPT-1β and MCD in response to MCT treatment (data not shown). Western blot analyses of protein levels showed similar results, except for that the protein expression level of PKM2 did not alter in response to MCT treatment ( Figure 5B ,C).
| Changes of genes and proteins involved in glucose and fatty acid metabolism in right hearts of MCT-induced PAH rat model
We investigated mRNA and protein expression levels of key enzymes in glucose and fatty acid metabolism in lungs. The results showed mRNA expression levels of LDHA, CD36, CPT-1β and FASN were significantly increased in right heart when rats were treated with MCT for 2 or 3 weeks, and mRNA expression of PDK-4 was significantly increased only in the third week of MCT treatment, compared with the control group (all P < .05) ( Figure 6A ). Western blot analyses of protein levels of showed similar results, except for that the protein expression level of PDK-4 did not alter in response to MCT treatment ( Figure 6B ,C).
| D ISCUSS I ON
Our study provides insight into the metabolic signatures of PAH with the potential to unravel novel biomarkers and therapeutic targets. In This effect of LDHA has been extensively studied in in vitro cancer models where tumour cells proliferate under hypoxic condition by suppression of mitochondrial respiration (Warburg effect). 20 Taken together, targeting the glycolysis and associated enzymes appears to be a lucrative therapeutic strategy in PAH. In this regard, GLUT1
facilitating the transport of glucose across the plasma membranes of cells is of considerable interest. Increase in GLUT1 and subsequent increase in glucose uptake has been implicated in providing a "glycolytic" metabolic profile in the lungs and heart in PAH patients from prior studies. [21] [22] [23] This effect was more pronounced in proliferating vascular cells in PAH rats, 22 and inhibition of GLUT1 expression has been demonstrated to reverse Warburg effect as well, 23 In present study, we report that the levels of l-carnitine, ace- in myocardium and accounts for approximately 70% of fatty acid uptake into contracting cardiomyocytes. 28 Our study found that CD36 expression was significantly up-regulated in lungs and hearts of MCT-induced PAH, which was consistent with previous studies in the field. 29, 30 Upregulation of CD36 expression increases fatty acid uptake resulting in excess lipid supply and subsequent lipid accumulation in lung and heart which can induce cardiac hypertrophy and contractile dysfunction. Studies have found that palmitic acid increases CD36 expression, and palmitoylation results in abnormal lipid accumulation in cells. 31 Since we had a significant increase in circulating palmitate, the upregulation of CD36 may be a sequelae to the metabolite. In addition, we have found that the levels of 2-Octenoylcarnitine and 9-decenoylcarnitine were decreased in the CHD-PAH patients. Given our limited understanding about these two lipid subtypes, the significance of these lipids in the circulation remains unknown. Future studies can explore the mechanistic basis of these metabolites in the circulation of PAH patients.
Another interesting finding in our study is the significantly re- induce pulmonary artery smooth muscle proliferation, vasoconstriction and microthrombosis and play a key role in the development of PAH. 32 Therefore, the decrease in tryptophan in our study may be related to the increased conversion of tryptophan to serotonin, which is contributory to the pulmonary artery endothelial proliferation and vascular remodelling. In addition, we found increased levels of l-phenylalanine in patients with IPAH, compared with healthy controls. This is significant considering the fact that ratio of (phenylalanine/tyrosine) elevation is considered as a biochemical marker for endothelial dysfunction, 33 emphasizing the endothelial dysfunction in our cohort of PAH patients.
In present study, we found an increase in levels of phosphatidylcholine (PC) and a decrease in levels of lysophosphatidylcholine (LysPC) in the PAH group, compared with that in the healthy controls. However, their role in disease pathogenesis is unclear and is an area of active research.
F I G U R E 6
Changes of genes and proteins involved in glucose and fatty acid metabolism in the hearts of the MCT-induced PAH rat model. Male SD rats (180 g) randomly received an intraperitoneal injection of normal saline (control, n = 12) or monocrotaline (MCT, n = 24) to induce PAH. The rats in control group were examined at the third week (day 21), and rats in MCT group were randomly examined at the second (day 14, MCT-2 wk, n = 12) and third week (day 21, MCT-3 wk, n = 12). The mRNA expressions of LDHA (a), CD36 (b), CPT-1 (c), FASN (d) and PDK4 (e) were tested by real-time PCR (A), relative protein levels of proteins were tested by Western blot (B), relative levels of LDHA, CD36, cpt-1β and FASN were calculated (C). *P < .05; **P < .01
| CON CLUS IONS
In conclusion, metabolic profiling in a Chinese population indicates towards a metabolic pathogenesis of PAH, highlighting the significance of these metabolites in biomarker discovery and devising therapeutic strategies.
